Daniel Abdun-Nabi is CEO & President at Emergent BioSolutions Inc. (EBS). They have made 14 open-market trades across 1 company since 2016, most recently 2019-03-04.
CIK 0001367644
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 14 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| EBS | 142,617 | $842K |
Shares reported on the most recent Form 4, priced at the 2019-03-04 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EBS | SELL | 2019-03-04 | 2019-03-04 | $58.11 | $846K | -12.3% | -10.9% | -25.1% |
| EBS | SELL | 2018-09-14 | 2018-09-18 | $65.00 | $1.9M | +0.8% | -5.5% | -6.8% |
| EBS | SELL | 2018-09-04 | 2018-09-06 | $60.18 | $5.5M | +11.8% | +10.4% | +17.8% |
| EBS | SELL | 2018-06-05 | 2018-06-07 | $52.11 | $823K | +1.7% | +1.2% | +12.9% |
| EBS | SELL | 2018-01-02 | 2018-01-04 | $47.91 | $1.0M | +3.8% | -4.9% | +9.4% |
| EBS | SELL | 2017-12-13 | 2017-12-14 | $45.99 | $920K | +2.2% | +4.5% | +13.9% |
| EBS | SELL | 2017-11-03 | 2017-11-07 | $42.77 | $1.3M | -2.6% | +9.4% | +17.7% |
| EBS | SELL | 2017-09-27 | 2017-09-29 | $39.92 | $599K | +0.0% | +1.3% | +17.9% |
| EBS | SELL | 2017-08-31 | 2017-09-05 | $37.21 | $558K | +3.5% | +10.1% | +19.3% |
| EBS | SELL | 2017-01-10 | 2017-01-12 | $31.28 | $883K | -1.0% | -2.1% | -5.8% |
| EBS | SELL | 2017-01-10 | 2017-01-12 | $31.28 | $883K | -1.0% | -2.1% | -5.8% |
| EBS | SELL | 2016-06-01 | 2016-06-03 | $43.74 | $380K | -5.6% | -34.0% | -69.7% |
| EBS | SELL | 2016-05-20 | 2016-05-24 | $42.00 | $365K | +3.7% | -28.1% | -67.4% |
| EBS | SELL | 2016-04-18 | 2016-04-20 | $40.17 | $350K | +1.8% | +7.7% | -22.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.